ARMO BioSciences’s Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival in Patients with Advanced Pancreatic Cancer, NSCLC, and RCC
ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced that clinical trial results on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) are being reported at the European Society of Medical Oncology (ESMO) 2017 Congress being held in Madrid, Spain, September 8-12, 2017. These presentations will include additional clinical trial results from the ongoing Phase 1b studies of AM0010 in pancreatic cancer, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC).
“As we continue to treat and follow up patients for longer durations in the Phase 1/1b clinical trial of our immunotherapy AM0010, we remain very encouraged by the response rates, survival observations, and safety profile that we observe in patients with different types of advanced cancer,” said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO BioSciences. “Our Phase 1/1b study of AM0010 has enrolled more than 350 advanced cancer patients and we are pleased to present updates at ESMO 2017. In patients with advanced pancreatic cancer, AM0010 in combination with FOLFOX has demonstrated promising efficacy and safety data to date, with a median overall survival of 10.2 months and one year survival rate of 43% after a median follow-up time of 17.6 months (range 11.3-21.3 months). In advanced NSCLC and metastatic RCC, the combination of AM0010 with either nivolumab or pembrolizumab induced high response rates and durable objective responses. It is particularly promising to see these high, durable responses in advanced NSCLC patients with low as well as high PD-L1 expression and in intermediate to poor risk advanced RCC patients who have received 2 or more prior therapies.”